41270-66-0

Basic information

• Product Name: 5-chloro-2,3-diphenylpyrazine
• Synonyms: 2-Chloro-5,6-diphenylpyrazine;Pyrazine, 5-chloro-2,3-diphenyl-
• CAS NO: 41270-66-0
• Molecular Formula: C₁₆H₁₁ClN₂
• Molecular Weight: 266.72494
• EINECS: 1592732-453-0
• Product Categories: Selexipag intermediate
• Mol File: 41270-66-0.mol
• Article Data: 8

Chemical Properties

• Melting Point: 126-128℃ (methanol )
• Boiling Point: 145°C/0.001mmHg(lit.)
• Appearance: /
• Density: 1 +-.0.06 g/cm3(Predicted)
• PKA: -2.16±0.10(Predicted)
• CAS DataBase Reference: 5-chloro-2,3-diphenylpyrazine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-chloro-2,3-diphenylpyrazine(41270-66-0)
• EPA Substance Registry System: 5-chloro-2,3-diphenylpyrazine(41270-66-0)

Safety Data

• Hazardous Substances Data: 41270-66-0(Hazardous Substances Data)

Usage

Uses

2-Chloro-5,6-diphenylpyrazine is a diphenylpyrazine derivative used in a study to determine a novel class of prostacyclin receptor agonists.

Upstream product

• 18591-57-6 2,3-Diphenyl-6-hydroxypyrazine 
• 61578-13-0 2,6-diphenylpyrazine 1-oxide 
• 243472-82-4 2,3-diphenyl-5-trimethylsilanyloxy-pyrazine 
• 18591-57-6 5,6-diphenyl-2-hydroxypyrazine 
• 1588-89-2 2,3-diphenylpyrazine 
• 1489-06-1 2,3-diphenyl-5,6-dihydropyrazine 
• 134-81-6 benzil 
• 103-29-7 1,1'-(1,2-ethanediyl)bisbenzene 

Downstream Products

• 102659-57-4 2,3-diphenyl-5-piperidino-pyrazine 
• 110249-96-2 2-(5,6-diphenyl-pyrazin-2-ylamino)-ethanol 
• 74152-20-8 N-(5,6-Diphenyl-pyrazin-2-yl)-acetamide 
• 73444-24-3 N-(5,6-diphenylpyrazin-2-yl)(methyl)amine 
• 1588-89-2 2,3-diphenylpyrazine 
• 36932-95-3 2-ethyl-5,6-diphenylpyrazine 
• 78605-07-9 2,3-diphenyl-5-methyl pyrazine 
• 81225-12-9 2-cyano-5,6-diphenylpyrazine 
• 118617-31-5 1-(5,6-diphenylpyrazin-2-yl)-2-(3,6-diisobutylpyrazin-2-yl)acetylene 
• 109191-94-8 3-(5,6-Diphenyl-pyrazin-2-yl)-prop-2-yn-1-ol 
• 67714-64-1 2-Dimethylamino-5,6-diphenylpyrazine 
• 109191-80-2 2,3-Diphenyl-5-phenylethynyl-pyrazine 
• 109191-87-9 5-Hex-1-ynyl-2,3-diphenyl-pyrazine 
• 41270-71-7 2-amino-5,6-diphenylpyrazine 

Relevant articles and documents

Method for preparing selexipag intermediate

The invention discloses a preparation method of a selexipag intermediate 5-chloro-2,3-diphenyl piperazine. The preparation method comprises the following steps: carrying out a reaction on 5,6-diphenyl-2-hydroxypyrazine with phosphorus oxychloride for 10-12 hours under heating, wherein an acid-binding agent is added into an organic solvent environment; adding the reaction product into ice water forcrystallization, and performing filtration and washing to obtain the 5-chloro-2,3-diphenyl piperazine. By means of the method, the defects of an existing method are overcome, wherein the use amount of phosphorus oxychloride is reduced, phosphorus-containing sewage discharge is reduced, and the obtained intermediate is high in purity, good in yield, simple to operate and suitable for industrial production.

PROCESS FOR THE PREPARATION OF DIPHENYLPYRAZINE DERIVATIVES

The present invention relates to a process for the preparation of amorphous Selexipag from Selexipag crystalline salts using a solvent.

3-(Piperidin-4-ylmethoxy)pyridine Containing Compounds Are Potent Inhibitors of Lysine Specific Demethylase 1

Methylation of histone lysine residues plays important roles in gene expression regulation as well as cancer initiation. Lysine specific demethylase 1 (LSD1) is responsible for maintaining balanced methylation levels at histone H3 lysine 4 (H3K4). LSD1 is a drug target for certain cancers, due to important functions of methylated H3K4 or LSD1 overexpression. We report the design, synthesis, and structure-activity relationships of 3-(piperidin-4-ylmethoxy)pyridine containing compounds as potent LSD1 inhibitors with Ki values as low as 29 nM. These compounds exhibited high selectivity (>160×) against related monoamine oxidase A and B. Enzyme kinetics and docking studies suggested they are competitive inhibitors against a dimethylated H3K4 substrate and provided a possible binding mode. The potent LSD1 inhibitors can increase cellular H3K4 methylation and strongly inhibit proliferation of several leukemia and solid tumor cells with EC50 values as low as 280 nM, while they had negligible effects on normal cells.